Immunotherapy with the PD-1 inhibitor pembrolizumab (Keytruda) induced durable responses in a phase 2 clinical trial of patients with Merkel-cell carcinoma (MCC) and the Merkel-cell polyomavirus (MCPyV), reported Paul T. Nghiem, MD, PhD, Head, University of Washington Dermatology, Seattle, at the 2016 American Association for Cancer Research annual meeting. Among 26 patients in the trial who received pembrolizumab, 12 of 14 patients who responded to pembrolizumab have ongoing responses after a median follow-up of 7.6 months, and the objective response rate (ORR) was 62% in patients with virus-positive tumors.
Surgery for the primary treatment of T1-T3 oropharynx squamous-­cell carcinoma (OPC) does not increase the cost of care, even for patients requiring adjuvant treatment, according to A. Daniel Pinheiro, MD, an otolaryngologist at Mercy Clinic Ear, Nose, and Throat-Surgery Center, Springfield, MO, who presented his findings at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
The chances for further policy changes in healthcare over the next several years are expected to be minimal, said panelists during a roundtable discussion at the 2016 National Comprehensive Cancer Network annual conference. The exception may be the Medicare Part B project for provider reimbursement for infused and injected drugs.
Patients with cancer increasingly wish to discuss costs with their oncologists, whose knowledge of treatment costs is limited. At the 2016 ASCO Quality Care Symposium, Nora B. Henrikson, PhD, MPH, of Group Health Research Institute, Seattle, WA, presented the results from a pilot project called OPT-IN, which aims at increasing clinician access to treatment prices in the clinical setting.
A higher score on a composite index of homologous recombination deficiency (HRD), indicating genomic instability, correlated with improved progression-free survival (PFS) and overall survival (OS) in patients with ovarian cancer who have received platinum-containing chemotherapy, according to results presented at the 2016 Society of Gynecologic Oncology annual meeting.
The evidence blocks were incorporated into the National Comprehensive Cancer Network (NCCN) clinical practice guidelines late last year and act as a visual representation of 5 key measures related to specific recommendations.
The updated National Comprehensive Cancer Network (NCCN) guideline (version 2.2016) for the management of advanced melanoma reflects the increasing role of immune checkpoint inhibitors and targeted agents, as more data establish their superior efficacy over traditional chemotherapy.
The population of patients with multiple myeloma who are eligible for therapy has been expanded to include asymptomatic patients with certain features, according to the most recent National Comprehensive Cancer Network (NCCN) guideline (version 3.2016).
  • Oncology Benchmarks Annual Report Shows New Patient Visits, Drug Spending Are Rising
  • Personalizing Therapy for Patients with Multiple Myeloma
  • Cabometyx Receives FDA Approval for Advanced Renal-Cell Carcinoma
  • Venclexta First BCL-2 Targeted Drug Approved for Patients with CLL plus 17p Deletion
  • First Blood Test for CRC Screening Approved by FDA
  • Defitelio FDA Approved for Hepatic Veno-Occlusive Disease After HSCT
Page 2 of 3
Results 11 - 20 of 23
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology